GED05 International Eczema Council / International Psoriasis Council
DESCRIPTION
Global Educational Day of Dermatology at the 2026 AAD Annual Meeting is an opportunity for international societies to hold an independent educational session the day before the official start of the AAD Annual Meeting on Thursday, March 26, 2026.
This International Eczema Council - International Psoriasis Council collaborative educational session will explore the clinical challenges of distinguishing between psoriasis and atopic dermatitis in non-classic presentations, including psoriasiform spongiotic dermatitis and paradoxical drug reactions induced by biologic therapies like anti-TNF or IL-17 inhibitors. Through case studies and evidence-based discussions, participants will learn how to recognize subtle diagnostic cues and apply the latest treatment strategies, incorporating histopathology and biomarkers into their treatment decisions. Attendees will gain practical tools to improve diagnostic confidence, optimize patient outcomes, and navigate the therapeutic complexities of inflammatory skin disease, including mechanistic insights for managing treatment-related rashes.
Speakers:
Alan Irvine, MD DSc / Dublin & Bruce Strober, MD PhD / New Haven
Amy Paller, MD MS / Chicago
Andrew Pink, BMedSci (Hons) BMBS PhD MRCP / London
Kilian Eyerich, MD, PhD / Stockholm
Michel Gilliet, MD / Lausanne
Jason Hawkes, MD MS FAAD
Kenneth Gordon, MD / Milwaukee
Shawn G. Kwatra, MD / Baltimore
Yael Anne Leshem, MD MCR / Tel Aviv
Lev Pavlovsky, MD PhD / Petah-Tikva
Curdin Conrad, MD / Lausanne
LEARNING OBJECTIVES
Analyze the diagnostic challenges of distinguishing psoriasis from atopic dermatitis in non-classic clinical presentations, including recognition of psoriasiform spongiotic dermatitis, by identifying at least three distinguishing clinical features.
Evaluate and apply advanced diagnostic strategies, such as histopathology and biomarker testing, to differentiate psoriasis, atopic dermatitis, and paradoxical drug reactions, demonstrating the ability to select at least two appropriate tools for challenging adult and pediatric cases.
Design and implement evidence-based management plans for paradoxical psoriasiform and eczematous eruptions associated with biologic therapies, including TNF-a or IL-17 inhibitors, integrating mechanistic insights to optimize skin-related outcomes for patients with psoriasis, atopic dermatitis, or inflammatory bowel disease.